Publications by authors named "J Daccache"
Article Synopsis
- Noninfectious cutaneous granulomatous disorders like cutaneous sarcoidosis, granuloma annulare, necrobiosis lipoidica, and necrobiotic xanthogranuloma exhibit distinct immune responses and histological features due to variations in macrophage inflammation.
- The study used spatial transcriptomics to analyze the immune activation patterns in these disorders, revealing that each condition has unique characteristics, such as polarized type 1 responses in cutaneous sarcoidosis and mixed type 1 and type 2 responses in granuloma annulare.
- Findings suggest that different immune activation patterns are associated with specific histological changes, highlighting the complexity and individuality of these inflammatory skin conditions.
Article Synopsis
- Granuloma annulare (GA) is a skin condition marked by granulomatous inflammation and influenced by both innate and adaptive immune responses, but its exact triggers and molecular mechanisms are not well understood.* -
- Macrophages are the primary immune cells responsible for the inflammation in GA, yet little is known about how they become activated and how the condition manifests at the molecular level.* -
- By studying the spatial gene expression of GA in six patients, researchers discovered a combination of immune signals and distinct macrophage polarization patterns, suggesting that key molecules like IFN-γ, TNF, and IL-32 play significant roles in the inflammation process related to GA.*
Inflammation is a hallmark of remitting-relapsing dermatological diseases. Although a large emphasis has been placed on adaptive immune cells as mediators of relapse, evidence in epithelial and innate immune biology suggests that disease memory is widespread. In this study, we bring to the fore the concept of inflammatory memory or nonspecific training of long-lived cells in the skin, highlighting the epigenetic and other mechanisms that propagate memory at the cellular level.
View Article and Find Full Text PDFSarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. An imprecise understanding of the immunologic changes underlying sarcoidosis has limited therapeutic progress. Here in this open-label trial (NCT03910543), 10 patients with cutaneous sarcoidosis are treated with tofacitinib, a Janus kinase inhibitor.
View Article and Find Full Text PDF